CLOZAPINE AND AGRANULOCYTOSIS: IMPACT OF THE RISK EVALUATION AND MITIGATION STRATEGY PROGRAM

被引：0

作者：

Borrelli, E. P. ^{[1
]}

Lee, E. Y. ^{[1
]}

Descoteaux, A. M. ^{[1
]}

Caffrey, A. R. ^{[1
]}

机构：

[1] Univ Rhode Isl, Coll Pharm, Kingston, RI 02881 USA

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.04.1228

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMH1

引用

页码：S180 / S180

页数：1

共 50 条

[1] Risk Evaluation and Mitigation Strategy for Clozapine
Cetin, Mesut
Sayar, Gokben Hizli
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (01): : 1 - 6
[2] Clozapine: risk of neutropenia and agranulocytosis
Reactions Weekly, 2004, 1027 (1) : 3 - 3
[3] Impact of risk evaluation and mitigation strategy (REMS) programs
Reactions Weekly, 2021, 1853 (1) : 7 - 7
[4] Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program
Auth, Doris
Staffa, Judy
LaCivita, Cynthia
JAMA INTERNAL MEDICINE, 2020, 180 (06) : 915 - 916
[5] CHANGES IN NEUTROPENIA OUTCOMES FOLLOWING IMPLEMENTATION OF THE CLOZAPINE RISK EVALUATION AND MITIGATION STRATEGY UPDATE
Chang, J.
Taylor, K.
Wei, Y.
Huang, T. Y.
VALUE IN HEALTH, 2024, 27 (06) : S156 - S156
[6] Changes in Neutropenia Outcomes after the 2019 Clozapine Risk Evaluation and Mitigation Strategy Update
Huang, Ting-Ying
Chang, Jana
Taylor, Kenneth
Wei, Yuqin
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 58 - 59
[7] Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program Reply
Heyward, James
Sharfstein, Joshua
Alexander, G. Caleb
JAMA INTERNAL MEDICINE, 2020, 180 (06) : 916 - 916
[8] Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing
Fleischman, William
Auth, Doris
Shah, Nilay D.
Agrawal, Shantanu
Ross, Joseph S.
JAMA NETWORK OPEN, 2019, 2 (03)
[9] SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program
Alford, Daniel P.
Zisblatt, Lara
Ng, Pamela
Hayes, Sean M.
Peloquin, Sophie
Hardesty, Ilana
White, Julie L.
PAIN MEDICINE, 2016, 17 (01) : 52 - 63
[10] Agranulocytosis risk with clozapine still needs monitoring
Reactions Weekly, 2018, 1694 (1) : 1 - 1

← 1 2 3 4 5 →